1. Home
  2. CBIO vs MTW Comparison

CBIO vs MTW Comparison

Compare CBIO & MTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$17.14

Market Cap

537.5M

Sector

N/A

ML Signal

N/A

Logo Manitowoc Company Inc. (The)

MTW

Manitowoc Company Inc. (The)

HOLD

Current Price

$20.68

Market Cap

498.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
MTW
Founded
2003
1902
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
537.5M
498.8M
IPO Year
2013
1994

Fundamental Metrics

Financial Performance
Metric
CBIO
MTW
Price
$17.14
$20.68
Analyst Decision
Strong Buy
Sell
Analyst Count
6
4
Target Price
$26.67
$10.50
AVG Volume (30 Days)
283.5K
321.1K
Earning Date
04-29-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.22
Revenue
$18,500.00
$2,240,900,000.00
Revenue This Year
N/A
$4.73
Revenue Next Year
$279.20
$2.98
P/E Ratio
N/A
$94.86
Revenue Growth
N/A
2.89
52 Week Low
$8.72
$9.15
52 Week High
$27.41
$20.92

Technical Indicators

Market Signals
Indicator
CBIO
MTW
Relative Strength Index (RSI) 54.19 82.54
Support Level $17.02 $11.68
Resistance Level $17.80 N/A
Average True Range (ATR) 1.12 0.81
MACD 0.21 0.67
Stochastic Oscillator 83.78 90.57

Price Performance

Historical Comparison
CBIO
MTW

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About MTW Manitowoc Company Inc. (The)

Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.

Share on Social Networks: